Biosimilar Approval Is New Focus In Senate Critique Of FDA Guidance Policy
This article was originally published in The Pink Sheet Daily
Commissioner Hamburg describes a Catch-22, warning that pressure to finalize guidances faster without more resources could result in fewer discretionary guidances, disappointing stakeholders.
You may also be interested in...
In an unusual move, industry rep indicates comfort with draft guidance implementing biosimilar pathway.
Republicans on the Senate HELP Committee say they are concerned that FDA is using draft guidance documents to set substantive policy, which they argue puts companies in a difficult position.
Ahead of the vaccine advisory committee, requests to FDA range from public health groups opposing emergency use authorizations to industry seeking labeling guidance on EUA products.